UB Paderborn / Katalog / Suche / in CDI

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer

BMC cancer, 2022-07, Vol.22 (1), p.820-14, Article 820

2022

Volltextzugriff (PDF)

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

BMC cancer, 2019-10, Vol.19 (1), p.990-990, Article 990

2019

Volltextzugriff (PDF)

Advantages of a multi-state approach in surgical research: how intermediate events and risk factor profile affect the prognosis of a patient with locally advanced rectal cancer

BMC medical research methodology, 2018-02, Vol.18 (1), p.23-23, Article 23

2018

Volltextzugriff (PDF)

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’

European journal of cancer (1990), 2018-05, Vol.94, p.95-103

2018

Volltextzugriff (PDF)

Reply to the Letter to the Editor ‘The Neonax study’ by M. W. Büchler and J. Neoptolemos

Annals of oncology, 2023-04, Vol.34 (4), p.443-445

2023

Volltextzugriff (PDF)

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Annals of oncology, 2020-02, Vol.31 (2), p.228-235

2020

Volltextzugriff (PDF)

Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information

Scientific reports, 2019-09, Vol.9 (1), p.13261-11, Article 13261

2019

Volltextzugriff (PDF)

Metastatic colorectal cancer-Modern treatment strategies and sequences

Innere Medizin (Heidelberg, Germany), 2023-06, Vol.64 (6), p.546

2023

Volltextzugriff (PDF)

EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity

Annals of oncology, 2018-04, Vol.29 (4), p.1010-1015

2018

Volltextzugriff (PDF)

A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma

Annals of oncology, 2018-10, Vol.29, p.viii663-viii663

2018

Volltextzugriff (PDF)

Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial

Annals of oncology, 2018-12, Vol.29 (12), p.2393-2395

2018

Volltextzugriff (PDF)

Genotyping of circulating tumor DNA in biliary tract cancer reveals diagnostic and prognostic information

Annals of oncology, 2018-10, Vol.29, p.viii660-viii660

2018

Volltextzugriff (PDF)

Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)

ESMO open, 2022-08, Vol.7 (4), p.100552, Article 100552

2022

Volltextzugriff (PDF)

Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii139-viii140

2018

Volltextzugriff (PDF)

A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii159

2018

Volltextzugriff (PDF)

TRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: Final results from the randomized phase II trial of the AIO

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii188-viii189

2018

Volltextzugriff (PDF)

Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial

ESMO open, 2022-02, Vol.7 (1), p.100391-100391, Article 100391

2022

Volltextzugriff (PDF)

Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study

ESMO open, 2022-02, Vol.7 (1), p.100388-100388, Article 100388

2022

Volltextzugriff (PDF)

Colon Polypectomy - And Then?

Zentralblatt fur Chirurgie, 2015-08, Vol.140 (4), p.426

2015

Volltextzugriff (PDF)

Metastasiertes kolorektales Karzinom – moderne Therapiestrategien und -sequenzen

Die Onkologie, 2024-03, Vol.30 (3), p.222-235

2024

Volltextzugriff (PDF)

787PMulticenter phase I/II feasibility study of adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (GMBH-STO-0114)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

580PQuality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Nal-IRI with 5-fluorouracil an open label, non-comparative, randomized, multicenter phase II study

BMC cancer, 2019-10

2019

Volltextzugriff (PDF)

581PA biomarker combination indicating resistance to FOLFOX plus bevacizumab in metastatic colorectal cancer: Results of phase I of the PERMAD trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

Advantages of a multi-state approach in surgical research: how intermediate events and risk factor profile affect the prognosis of a patient with locally advanced rectal cancer

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’

Reply to the Letter to the Editor ‘The Neonax study’ by M. W. Büchler and J. Neoptolemos

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information

Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group

Metastatic colorectal cancer-Modern treatment strategies and sequences

EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity

A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma

Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial

Genotyping of circulating tumor DNA in biliary tract cancer reveals diagnostic and prognostic information

Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)

Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma

A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial

TRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: Final results from the randomized phase II trial of the AIO

Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial

Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study

Colon Polypectomy - And Then?

Metastasiertes kolorektales Karzinom – moderne Therapiestrategien und -sequenzen

787PMulticenter phase I/II feasibility study of adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (GMBH-STO-0114)

580PQuality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)

Nal-IRI with 5-fluorouracil an open label, non-comparative, randomized, multicenter phase II study

581PA biomarker combination indicating resistance to FOLFOX plus bevacizumab in metastatic colorectal cancer: Results of phase I of the PERMAD trial

Suchergebnisse filtern